This comes together at exactly the point in time that PGC completes it's Immunolab expansion.
John Walstab is experienced in the Asian Market.
PGC has long ben pushin to get into the Aian market this will give them clout. The merged company will give PGC better exposure to the Australian hospital sector.
CH2 is well liked in the Hospital sector but has NO access to Asian markets at present.
End result is that both companies get access to very much larher markets and therefore growth potential.
Makes sense to me.
Ann: PGC-CH2 Merger Presentation, page-29
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $670.3M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 41.0¢ | 40.5¢ | $130.2K | 321.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23000 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 46165 | 3 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| PGC (ASX) Chart |